The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Arrowhead Pharmaceuticals Inc. (ARWR) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.01, or -0.04%, to $26.92. The Arrowhead Pharmaceuticals Inc. has recorded 27,524 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare Conference.
Arrowhead Pharmaceuticals Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Arrowhead Pharmaceuticals Inc. is $2.89B. A total of 1.22 million shares were traded on the day, compared to an average of 973.16K shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, ARWR has seen 1 BUY and 3 SELL insider trades, representing the acquisition of 57,755 and the disposition of 59,305 shares. Over the last 12 months, there were 17 BUYs and 37 SELLs from insiders. Insiders purchased 739,785 shares during that period but sold 321,613.
In the most recent transaction, Anzalone Christopher Richard sold 24,338 shares of ARWR for 24.21 per share on Oct 25. After the transaction, the Chief Executive Officer now owns 3,737,000 company shares. In a previous transaction on Sep 28, Vakiener Victoria sold 1,550 shares at 26.33 per share. ARWR shares that Director owns now total 21,734.
Among the insiders who sold shares, Anzalone Christopher Richard disposed of 57,755 shares on Sep 18 at a per-share price of $28.12. This resulted in the Chief Executive Officer holding 3,761,338 shares of ARWR after the transaction. In another insider transaction, Oliver Tracie sold 8,925 shares at $35.31 per share on Jul 03. Company shares held by the Chief Commercial Officer now total 61,575.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for ARWR in the last 3 months, the mean price target is $55.93 with high estimates of $90.00 and low estimates of $26.00. In terms of 52-week highs and lows, ARWR has a high of $42.48 and a low of $22.87.
As of this writing, ARWR has an earnings estimate of -$0.6 per share for the current quarter. EPS was calculated based on a consensus of 13 estimates, with a high estimate of $0.75 per share and a lower estimate of -$0.99. The company reported an EPS of $0.45 in the last quarter, which was 170.30% higher than expectations of -$0.64.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ARWR’s latest balance sheet shows that the firm has $367.79M in Cash & Short Term Investments as of fiscal 2021. There were $25.55M in debt and $146.54M in liabilities at the time. Its Book Value Per Share was $3.41, while its Total Shareholder’s Equity was $408.82M.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ARWR is Buy with a score of 4.36.